ACQUISITION, Part IV (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended			9 Months Ended		12 Months Ended	21 Months Ended
	Sep. 30, 2012	Jun. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Sep. 30, 2012	Jun. 25, 2012
Unaudited pro forma financial information [Abstract]
Revenues	$ 79,624		$ 82,122	$ 247,021	$ 256,035
Net (loss) income	(17,643)		(17,128)	(36,399)	(8,528)
Business Acquisition, Pro Forma Earnings Per Share, Basic and Diluted	$ (0.25)		$ (0.25)	$ (0.52)	$ (0.12)
Business Acquisition, Cost of Acquired Entity, Acceleration of Stock Options								8,265
Income tax (benefit) provision related to acquisition		37,462		37,462
Business Acquisition, Cost of Acquired Entity, Transaction Costs Duration	266			6,032	0	2,936	8,968
Business Acquisition, Cost of Acquired Entity, Transaction Costs incurred by eBioscience	$ 60			$ 5,530	$ 126